GE Healthcare has received clearance from the U.S. Food and Drug Administration (FDA) for AngioViz, an application that enables doctors to visualize vascular flow on a single image during interventional radiology procedures.
AngioViz yields its information from digital subtraction angiography (DSA) studies, using a technique called parametric imaging. With parametric imaging, each pixel in an image series is examined to determine the peak-value opacification caused by the contrast, as well as the time it takes for that pixel to reach peak opacification.
These two parameters can be displayed as separate images or combined into a single color-coded image that represents parameters of vascular flow, GE said.
